论文部分内容阅读
目的：探讨ｂｃｌ－２基因与肝癌发生的关系。方法：采用半套式原位聚合酶链反应和免疫组化技术原位检测５４例肝癌中ｂｃｌ－２／ＪＨ融合基因和ｂｃｌ－２蛋白表达。结果：４０例肝细胞癌中６例ｂｃｌ－２蛋白阳性，阳性率为１５％，发生ｂｃｌ－２基因重排１０例，阳性率为２５％，ｍｂｒ和ｍｃｒ阳性各５例；１４例肝胆管癌中ｂｃｌ－２蛋白阳性１０例，阳性率７１．４％，未发现ｂｃｌ－２／ＪＨ融合基因。结论：ｂｃｌ－２／ＪＨ融合基因形成和ｂｃｌ－２蛋白表达与肝细胞癌和肝胆管癌的发生有一定关系，而ｂｃｌ－２蛋白表达与ｂｃｌ－２基因重排之间无相互对应关系，因此两者在肝癌发生中的作用可能不同
Objective: To investigate the relationship between bcl-2 gene and the occurrence of hepatocellular carcinoma. Methods: The expression of bcl-2/JH fusion gene and bcl-2 protein were detected in situ in 54 cases of hepatocellular carcinoma by using half-in-situ polymerase chain reaction and immunohistochemistry. Results: Of the 40 cases of hepatocellular carcinoma, 6 cases were positive for bcl-2 protein, with a positive rate of 15%. There were 10 cases of bcl-2 gene rearrangement, the positive rate was 25%, 5 cases were mbr and mcr positive, and 14 cases were hepatobiliary. There were 10 cases of positive bcl-2 protein in the cancer and the positive rate was 71.4%. No bcl-2/JH fusion gene was found. CONCLUSION: The bcl-2/JH fusion gene formation and bcl-2 protein expression are related to the occurrence of hepatocellular carcinoma and hepatobiliary carcinoma. There is no corresponding relationship between bcl-2 protein expression and bcl-2 gene rearrangement. Therefore, the role of both may be different in the occurrence of liver cancer.